The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Complete radiographic responses in pediatric patients with BRAFV600-positive tumors including high-grade gliomas: Preliminary results of an ongoing phase 1/2a safety and pharmacokinetics (PK) study of dabrafenib.
Mark W. Kieran
No relevant relationships to disclose
Kenneth J. Cohen
Research Funding - GlaxoSmithKline
Francois Doz
No relevant relationships to disclose
Ira J. Dunkel
Research Funding - GlaxoSmithKline
Darren R Hargrave
No relevant relationships to disclose
Trent Ryan Hummel
No relevant relationships to disclose
Irene Jimenez
No relevant relationships to disclose
Sarah Leary
Research Funding - GlaxoSmithKline
Andrew DJ Pearson
No relevant relationships to disclose
Christine A. Pratilas
Research Funding - GlaxoSmithKline
James Whitlock
Consultant or Advisory Role - GlaxoSmithKline (U)
Research Funding - GlaxoSmithKline
Michael Durante
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Diana M. Gibson
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Patricia Haney
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Mark W. Russo
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Benjamin B. Suttle
Employment or Leadership Position - GlaxoSmithKline
Stock Ownership - GlaxoSmithKline
Birgit Geoerger
No relevant relationships to disclose